This article is more than 5 years old. Information may no longer be current.

Generic epinastine solution gets FDA approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALLEGAN, Mich. — A generic version of Elestat has received final approval from the U.S. Food and Drug Administration and will begin shipping immediately, Perrigo Company announced in a press release.

Elestat (epinastine HCl ophthalmic solution 0.05%, Allergan) generates about $30 million in sales each year as a treatment for ocular itching associated with allergic conjunctivitis, the release said.

"Perrigo is excited to launch another new product in the ophthalmic category as part of our extended topical strategy," Joseph C. Papa, Perrigo chairman and CEO, said in the release. "This product is another example of Perrigo's commitment to expand our portfolio and bring new products to market. It further demonstrates our strategy to deliver quality affordable health care products."

Perrigo's partner, PharmaForce/Luitpold Pharmaceuticals, received the approval and will produce the epinastine solution, according to the release.